Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

New research on bariatric surgery and transcatheter heart valve implantation.

You may also be interested in...



Panel Supports Sapien But Urges Cautious Rollout

Edwards Lifesciences’ Sapien transcatheter aortic valve met widespread expectations last week by gaining support for FDA approval from an agency advisory panel, but the experts urged FDA and Edwards to proceed cautiously.

Milan Will Host The Global Generics & Biosimilars Awards 2020

Informa Pharma Intelligence has officially launched the seventh Global Generics & Biosimilars Awards, which will take place in October 2020 in Milan, Italy.

Mylan Weighs In On Coronavirus Drug Shortage Concerns

Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business. 

Topics

UsernamePublicRestriction

Register

MT031676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel